Variability in microwave ablation size for liver tumors
Official title: Variability of Microwave Ablation Volume Based on Clinical, Radiological, Biological, and Tissue Factors : a Retrospective Study
Run by Central Hospital, Nancy, France · NCT07413640 · Data updated 2026-11-12
This project will see if patient and tumor features change the size and shape of microwave ablation zones in adults treated for liver tumors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | July 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT07413640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults undergoing percutaneous hepatic microwave ablation at CHRU Nancy who have manufacturer planned ablation data and available contrast-enhanced follow-up imaging between 1 and 4 months are ideal candidates.
✕Probably not a fit
Patients without manufacturer planned-volume data, without adequate post-procedure contrast imaging, or who had repeat treatment/reoperation on the same lesion are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study of adults treated with percutaneous microwave ablation for one or more liver lesions at a single center. Planned ablation dimensions from manufacturer tables will be compared with ablation size measured on immediate post-procedure CT and on CT or MRI at 6–12 weeks, accounting for expected tissue shrinkage. The analysis will examine patient-related factors (liver fibrosis, steatosis, portal flow) and tumor-related factors (location, histology, prior treatments) to explain differences between planned and actual ablation volumes. Cases with missing manufacturer data, repeat treatments on the same lesion during the same session, or without suitable follow-up imaging will be excluded.
Why it matters
Potential benefit: If successful, the findings could help clinicians better predict ablation zones and personalize planning to reduce under-treatment or unnecessary damage to healthy liver.
How similar studies have gone: Retrospective reports have documented discrepancies between planned and actual ablation sizes, but prospective, systematic quantification that accounts for both patient and tumor factors remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients * Treated with percutaneous hepatic microwave ablation under CT or ultrasound guidance * Adult treated for one or more liver lesions * Patients with available follow-up imaging Exclusion Criteria: * Two treatment cycles on the same lesion during the same session. * Reoperation on the same lesion. * Planned volume not available (no manufacturer data, not specified in the surgical report). * No control imaging injected between 1 and 4 months post-procedure. * Final ablation volume not measurable (e.g., artifacts, no injection on MRI). * No definitive diagnosis of the nature of the tumor on imaging and no histology available.
Where it's running
-
CHRU Nancy
Vandœuvre-lès-Nancy, France Recruiting
Study contacts
- Study coordinator: Valérie LAURENT, MD-PhD
- Email: v.laurent@chru-nancy.fr
- Phone: 33383157823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting heart injury after major liver and biliary surgery
We test whether a stepwise prediction model using routine clinical data, the type and timing of liver blood-flow control (SPVO vs Pringle), and simple blood markers can predict heart injury (MINS) after major hepatobiliary surgery in adults.
-
Single-cell and spatial mapping of liver degeneration and regeneration
This project will try to use single-cell and spatial omics on preoperative blood and discarded liver tissue from people having liver surgery or biopsy to map how cells change during fatty liver, HBV infection, fibrosis, and cirrhosis.
-
Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer
This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.
-
Combining DEBIRI with chemotherapy for colorectal cancer liver metastases
This study is testing if adding a special treatment called DEBIRI to regular chemotherapy can help patients with colorectal cancer that has spread to the liver feel better and possibly have surgery later.
-
Using contrast agents to improve liver cancer radiation therapy
This study is testing if using special contrast agents can help doctors better track liver tumors during radiation therapy for patients who have already received a different treatment.
-
T-Cell Therapy for Advanced Liver Cancer
This study is testing a new T-cell therapy to see if it can help adults with advanced liver cancer that has a specific marker called GPC3.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.